VRI to go >>>, page-2

  1. 3,044 Posts.
    lightbulb Created with Sketch. 129
    re: VRI to go ProBio PCC Launch Date Announced in

    HOMEX - Perth

    Following on from the highly successful trade launch at the
    Pharmanex, Inc International Distributor Convention in September
    (Salt Lake, Utah), VRI Biomedical is delighted to announce that
    Pharmanex has confirmed that ProBio PCC(TM) will rollout into all US
    states on November 6, 2002.

    Pharmanex describes ProBio PCC(TM) as a superior intestinal health
    formula and will replace their previous product in this category. It
    will be sold in the US as a dietary supplement to maintain a healthy
    gastrointestinal environment. ProBio PCC(TM) recorded sell-out sales
    at the trade launch.

    VRI BioMedical this week received feedback from Pharmanex indicating
    that impressive health improvement outcomes are already being
    reported from distributors using the product in the US. According to
    Pharmanex, ProBio PCC(TM) has already been effective in aiding people
    infected with intestinal microbial infections, people who are
    recovering from aggressive antibiotic treatments as well as one
    person who had suffered for more than a decade with irritable bowel
    syndrome (until now).

    Mr Leon Ivory, VRI Biomedical Executive Chairman, said that it was
    particularly gratifying to receive such strong independent validation
    for the product, support that is likely to drive sales when ProBio
    PCC(TM) rolls out in the US in November.

    Additional information regarding ProBio PCC(TM) can be found on the
    Pharmanex website at www.pharmanex.com/products/probio.shtml.

    VRI BioMedical is a global leader in the field of probiotic research
    and product development, based on an effective clinical programme.

    For further information please contact:

    Leon Ivory, Executive Chairman on 0419428264, or
    John Frame, Company Secretary on (08) 93213655.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.